This article introduces the technology that powers automated HT–DLS and explores its practical applications in enhancing formulation stability investigations.
BioPharm International
eBooks Volume 28, Issue 14
Assessing a drug candidate’s suitability during preformulation is essential to minimize the risk of costly downstream failure. Stability is a defining feature of biotherapeutic performance; measuring formulation stability during early-phase screening allows developers to make robust predictions of suitability for further development. Read this article and other articles in
BioPharm International
's 2015
The Future of BioprocessingeBook.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.